Spontaneous mutation frequency and emergence of ciprofloxacin resistance in Campylobacter jejuni and Campylobacter coli

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 6, 2007, Pages 1251-1257

  Hänninen, Marja Lisa ^a   Hannula, Minna ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Antimicrobials; CmeABC; gyrA

Indexed keywords

AMPICILLIN; ASPARAGINE; ASPARTIC ACID; BACTERIAL PROTEIN; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ERYTHROMYCIN; ISOLEUCINE; PROTEIN CMEA; PROTEIN CMEABC; PROTEIN CMER; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; THREONINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM COLONY; CAMPYLOBACTER COLI; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; INVERTED REPEAT; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; PROMOTER REGION; SPONTANEOUS MUTATION; STRAIN DIFFERENCE;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; BASE SEQUENCE; CAMPYLOBACTER COLI; CAMPYLOBACTER JEJUNI; CIPROFLOXACIN; DNA GYRASE; DNA, INTERGENIC; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION;

EID: 36448940487     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm345     Document Type: Article

References (31)

1. Friedman CR, Neimann J, Waegener HG et aL. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In: Nachamkin I, Blaser MJ, eds. Campylobacter, 2nd edn. Washington, DC: American Society for Microbiology, 2000; 121-39.
2. Rautelin H, Hänninen ML. Campylobacters: The most common bacterial enteropathogens in the Nordic countries. Ann Med 2000; 32: 440-5.
3. Endtz H, Ruijs G, van Klingeren B. Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother 1991; 27: 199-208.
4. Engberg J, Aarestrup F, Taylor D. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli. resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001; 7: 24-34.
5. Farnell MBA, Donoghue M, Cole K et al. Campylobacter susceptibility to ciprofloxacin and corresponding fluoroquinolone concentrations within the gastrointestinal tracts of chickens. J Appl Microbiol 2005; 99: 1043-50.
6. Griggs DJ, Johnson MM, Frost JA et al. Incidence and mechanism of ciprofloxacin resistance in Campylobacter spp. isolated from commercial poultry flocks in the United Kingdom before, during, and after fluoroquinolone treatment. Antimicrob Agents Chemother 2005; 49: 699-707.
7. Luo N, Sahin O, Lin J et al. In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump. Antimicrob Agents Chemother 2003; 47: 390-4.
8. Luo N, Pereira S, Sahin O et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc Natl Acad Sci USA 2005; 102 541-6.
9. Lin J, Michel LO, Zhang Q. CmeABC functions as a multidrug efflux system in Campylobacter jejuni. Antimicrob Agents Chemother 2002; 26: 2124-31.
10. Pumbwe L, Piddock LJ. Identification and molecular characterisation of CmeB, a Campylobacter jejuni multidrug efflux pump. FEMS Microbiol Lett 2002; 206: 185-9.
11. Ge B, McDermott PF, White DG et al. Role of efflux pumps and topoisomerase mutations in fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother 2005; 49: 3347-54.
12. Willmott CJ, Maxwell A. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob Agents Chemother 1993; 37: 126-7.
13. Bachoual S, Ouabdesselams, Mory F et al. Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Microb Drug Resist 2001; 7: 257-61.
14. Piddock LJ, Ricci V, Pumbwe L et al. Fluoroquinolone resistance in Campylobacter species from man and animals: Detection of mutations in topoisomerase genes. J Antimicrob Chemother 2003; 51: 19-26.
15. Lin J, Akiba M, Sahin O et al. CmeR functions as a transcriptional repressor for the multidrug efflux pump CmeABC in Campylobacter jejuni. Antimicrob Agents Chemother 2005; 49: 1067-75.
16. Lin J, Gagliero C, Guo B et al. Bile salts modulate expression of the CmeABC multidrug efflux pump in Campylobacter jejuni. J Bacteriol 2005; 187: 7417-24.
17. Hakanen AJ, Lehtopolku M, Siitonen A et al. Multidrug resistance in Campylobacter jejuni strains collected from Finnish patients during 1995-2000. J. Antimicrob Chemother 2003; 52: 1035-9.
18. Pumbwe L, Randall LP, Woodward MJ et al. Evidence for multiple-antibiotic resistance in Campylobacter jejuni not mediated by CmeB or CmeF. Antimicrob Agents Chemother 2005; 49 1289-93.
19. Bjedov I, Tenaillon O, Gérard B et al. Stress-induced mutagenesis in bacteria. Science 2003; 300: 1404-9.
20. Bridges BA. Hypermutation in bacteria and other cellular systems. Philos Trans R Soc Lond Biol Sci 2001; 356: 29-39.
21. Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 2000; 44: 1771-7.
22. Chopra I, O'Neill AJ, Miller K. The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updates 2003; 6: 137-45.
23. Baquero MR, Nilsson AI, del Turrientes M et al. Polymorphic mutation frequencies in Escherichia coli: Emergence of weak mutators in clinical isolates. J Bacteriol 2004; 186: 5538-42.
24. Björkholm B, Sjölund M, Falk PG et al. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc Natl Acad Sci USA 2001; 98: 14607-12.
25. Wang G, Wilson TJM, Jiang Q et al. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylon. Antimicrob Agents Chemother 2001; 45: 727-33.
26. McDermott P, Bodeis S, Aarestrup F et al. Development of a standardized susceptibility test for Campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem. Microb Drug Resist 2004; 10: 124-31.
27. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-515. CLSI, Wayne, PA, USA, 2005.
28. Yan M, Sahin O, Lin J et al. Role of the CmeABC efflux pump in the emergence of fluoroquinolone-resistant Campylobacter under selection pressure. J Antimicrob Chemother 2006; 58: 1154-9.
29. Martinez JL, Baquero F. Interactions among strategies associated with bacterial infection: Pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev 2005; 15: 647-9.
30. Gunn JS. Mechanism and bacterial response to bile. Microbes Infect 2000; 2: 907-13.
31. Cagliero C, Maurel MC, Cloeckaert A et al. Regulation of the expression of the CmeABC efflux pump in Campylobacter jejuni: identification of a point mutation abolishing the binding of the CmeR repressor in an in vitro selected multidrug-resistant mutant. FEMS Microbiol Lett 2007; 267: 89-94.